semaglutide cancer risk GLP-1 drugs and cancer: the headline is exciting. The full picture is more nuanced. New research from @ascocancer 2026 shows patients on GLP-1 medications like were up to 50% less likely How Semaglutide May Reduce The

46, M84-90

Do I need to have any monitoring or tests while on sermorelin

Tirzepatide is a dual agonist targeting both GLP-1 and GIP receptors, improving insulin sensitivity and promoting fullness, leading to superior weight losssome patients lose over 20%, with an average of 15%

The most common side effects are gastrointestinal, including nausea, vomiting, diarrhoea, and abdominal discomfort, which are usually mild

Separate vials is the standard format

Though many in the traditional medical community reject the idea of chronic Lyme disease, Functional Medicine finds that many people with long-term symptoms exist, and takes a unique approach to relieving chronic Lyme disease and restoring immune function